Table 1. Preoperative characteristics of patients.
| Patients with postoperative hyponatremia | Patients without postoperative hyponatremia | p-value | |
|---|---|---|---|
| Number of patients | 93 | 1,250 | |
| Age (year) | 44.7 | 43.1 | 0.692 |
| Sex (male:female) | 0.925 | 482: 768 | 0.002† |
| Hardy classification (%) | 0.199 | ||
| I | 31 (33.3) | 298 (23.8) | |
| II | 15 (16.1) | 234 (18.7) | |
| III | 31 (33.3) | 437 (35.0) | |
| IV | 16 (17.2) | 281 (22.5) | |
| Tumor size (mm) | 19.71±11.54 | 19.29±9.96 | 0.245 |
| Hormonal type (%) | 0.490 | ||
| NFT | 41 (44.1) | 592 (47.4) | |
| GH | 33 (35.5) | 388 (31.0) | |
| PRL | 11 (11.8) | 150 (12.0) | |
| ACTH | 8 (8.6) | 88 (7.0) | |
| TSH | 0 (0.0) | 32 (2.6) | |
| Hormonal activity (hormonally active: inactive) | 52:41 | 658:592 | 0.542 |
| Preoperative hypopituitarism/total patients evaluated by CPFT* | 55/94 (58.5) | 862/1,205 (71.5) | 0.007† |
| Subnormal response in ACTH axis/total patients evaluated by CPFT* | 22/90 (24.4) | 325/1,209 (26.9) | 0.614 |
*Patients without preoperative CPFT were excluded, †p<0.05. ACTH, adrenocorticotropin hormone; CPFT, combined pituitary function test; GH, growth hormone; NFT, non-functioning tumor; PRL, prolactin; TSH, thyroid stimulating hormone